TY - JOUR T1 - Response to: ‘Potential roles for tenascin in (very) early diagnosis and treatment of rheumatoid arthritis’ by Cutolo <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e43 LP - e43 DO - 10.1136/annrheumdis-2019-215108 VL - 79 IS - 4 AU - Susan Aungier AU - Alison J Cartwright AU - Anja Schwenzer AU - Jennifer Marshall AU - Mike R Dyson AU - Peter Slavny AU - Kothai Parthiban AU - Aneesh Karatt-Vellatt AU - Ilfita Sahbudin AU - Eric Culbert AU - Patrick Hextall AU - Felix IL Clanchy AU - Richard Williams AU - Brian D Marsden AU - Karim Raza AU - Andrew Filer AU - Christopher D Buckley AU - John McCafferty AU - Kim S Midwood Y1 - 2020/04/01 UR - http://ard.bmj.com/content/79/4/e43.abstract N2 - We thank the authors for their commentary1 on our article which was recently published in the Annals of Rheumatic Diseases.2 Cutolo et al write an extended discussion of the study, in which we describe the development of therapeutic monoclonal antibodies that block the pro-inflammatory activity of the fibrinogen-like globe (FBG) domain of tenascin-C, and the efficacy of these antibodies in preventing disease progression in preclinical models of rheumatoid arthritis (RA). The commentary includes a detailed summary of the autoantibody response to a citrullinated epitope (cTNC5) within the FBG domain of tenascin-C which arises very early during the development of RA, and which can also be detected in around one in five people at risk of developing RA. As highlighted by the authors, the questions around how the response … ER -